Previous 10 | Next 10 |
home / stock / esalf / esalf news
Eisai Co., Ltd. (ESALF) Q3 2022 Earnings Conference Call February 3, 2022, 2:00 AM ET Company Participants Dr. Ryohei Yanagi - Chief Financial Officer Ivan Cheung - President, Neurology Business Group Dr. Takashi Owa - President, Oncology Business Group Teruyuki Masaka - In-charge, Business P...
Eisai press release (OTCPK:ESALF): 9M GAAP EPS of ¥210.50. Revenue of ¥565.3B (+13.4% Y/Y). For further details see: Eisai GAAP EPS of ¥210.50, revenue of ¥565.3B
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
Galapagos is in the midst of a transformation process that is expected to result in a completely different company by 2023. Galapagos has over $5.5 billion in cash, an approved drug and a broad pipeline with a market capitalization of only $3.2 billion. Jyseleca is approved in Jap...
Eisai Co., Ltd. (ESALF) Q2 2022 Earnings Conference Call November 1, 2021 03:00 AM ET Company Participants Haruo Naito - CEO Ivan Cheung - President, Neurology Conference Call Participants Hidemaru Yamaguchi - Citigroup Shinichiro Muraoka - Morgan Stanley Fumiyoshi Sakai - Crédit Suisse ...
The following slide deck was published by Eisai Co., Ltd. in conjunction with their 2022 Q2 earnings call. For further details see: Eisai Co., Ltd. 2022 Q2 - Results - Earnings Call Presentation
Eisai (OTCPK:ESALF): 1H GAAP EPS of ¥161.08. Revenue of ¥362.35B (+14.3% Y/Y) Press Release FY2021 guidance: Revenue of ¥730B; Profit for the year attributable to owners of the parent ¥60.5B and EPS per basic share of ¥211.00. For further de...
Radius Health (RDUS +15.2%) has recorded the biggest intraday gain since May to reach a three-month high after the company announced that its experimental therapy elacestrant met the primary endpoint in a late-stage trial for certain patients with breast cancer. Out-licensed to Menarini ...
Biogen (NASDAQ:BIIB) is scheduled to announce Q3 earnings results on Wednesday, October 20th, before market open. The consensus EPS Estimate is $4.11 (-53.5% Y/Y) and the consensus Revenue Estimate is $2.67B (-21.0% Y/Y). Over the last 2 years, BIIB has beaten EPS estimates 88% of the time an...
With a list of 62 recent IPOs making entry to The Russell 2000 small-cap index after index provider FTSE Russell implemented its Q3 recalibrations, we discuss the recently-IPOd healthcare stocks joining the index. Following up on our previous article on biotech stocks in the group, ...
News, Short Squeeze, Breakout and More Instantly...
Eisai Co Ltd Company Name:
ESALF Stock Symbol:
OTCMKTS Market:
"LEQEMBI" Lecanemab) Approved for the Treatment of Alzheimer's Disease in Israel TOKYO and CAMBRIDGE, Mass., July 12, 2024 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody "LEQEMB...
"LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Hong Kong TOKYO and CAMBRIDGE, Mass., July 11, 2024 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that the Department of Health in HongKong has approved humanized anti-soluble aggregated ...
Eisai Announces Move to Solo Development and Commercialization of Farletuzumab Ecteribulin (FZEC) Antibody Drug Conjugate (ADC) TOKYO, July 2, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has agreed to end its global strategic collaboration with Bristol Myers Squi...